Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimer's Disease
Authors: Shie, Feng-Shiun; Woltjer, Randall L.
Source: Current Medicinal Chemistry, Volume 14, Number 27, November 2007 , pp. 2865-2871(7)
Publisher: Bentham Science Publishers
Abstract:Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-amyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia- mediated neuroinflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.
Document Type: Research Article
Affiliations: Division of Mental Health and Substance Abuse, National Health Research Institutes, No.35 Keyan Road, Zhunan Town, Miaoli County 350, R.O.C., Taiwan.
Publication date: 2007-11-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.